Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)

Egyptian Liver Journal

Table 3 Non-invasive biomarkers of liver fibrosis at baseline and follow-up

Item	Baseline “n = 100”	3 months after the end of treatment “n = 100”	12 months after the end of treatment “n = 100”	P value
FIB4 (mean ± SD)	3.93 ± 2.78	3.28 ± 1.21 P1 < 0.001**	2.89 ± 1.69 P2 < 0.001**	P < 0.01* P3 < 0.01*
Stage of fibrosis
• F3 • F4	0 100 (100%)	1(1%) 99(99%) P1 = 0.678	8(8%) 92(92%) P2 < 0.04*	P < 0.02* P3 < .04*
SWE”KPa” (mean ± SD)	19.80 ± 7.90	15.88 ± 6.42 P1 < 0.04*	13.77 ± 5.42 P2 < 0.001**	P < 0.001 ** P3 < 0.02*
APRI score	1.46 ± 0.42	1.13 ± 0.44 P1 < 0.001**	0.86 ± 0.37 P2 < 0.000***	P < 0.001 ** P3 < 0.02*

APRI AST/PLT ratio index, SWE Share wave elastography, FIB4 Fibrosis score 4
P: comparison between baseline and 3 and 12 months after the end of treatment
P1: comparison between baseline and 3 months after the end of treatment
P2: comparison between baseline and 12 months after the end of treatment
P3: comparison between 3 and 12 months after the end of treatment